1. P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY. (23rd June 2022) Authors: Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 903 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE. (23rd June 2022) Authors: Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 904 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY. (23rd June 2022) Authors: Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 905 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗